MPT WWW
Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.

Commentary

Death in the shade of world’s attention
Jerry Norris, Business Day, 12-15-06

Norris argues that treating chronic diseases like cancer and heart disease in the developing world should become a higher international priority.

Somehow, policy makers seem to labour under the misapprehension that cancer and heart attacks are not emergencies or that they are more expensive to treat than HIV/AIDS. Nothing could be further from the truth. The WHO states unequivocally that 40% of cancers can be prevented "and that many solutions are also inexpensive to implement."

HIV/ AIDS, of course, remains incurable and palliative treatment is expensive, complicated and long-term.

SA's Medical Research Council and the WHO Collaborating Centre published a report in 2001 on chronic diseases in SA. Heart disease was found to account for 38% of all deaths from chronic disease, followed by cancer at 20,4%. Of those cancers, cervical and breast were the two biggest killers: "Death due to cancer of the cervix is the commonest cause of cancer deaths among poor women," frequently heads of households. This means that women suffer disproportionately from cancer during their most productive years and when they are most essential to their families.

South African men have a high rate of death from liver cancer but a cheap preventive intervention has been put in place by the government. The hepatitis B vaccination is now part of the Expanded Programme of Immunisation and all children should receive it.

Compared to AIDS, this seems like a cost-effective use of resources that will save many lives. On AIDS, the International Monetary Fund states that $8bn was spent in 2004; WHO says it rose to $8,3bn in 2005. This year, it is likely to be at least $9bn. That comes to $25,3bn over the past three years. But on World AIDS Day on December 1, UNAIDS announced that the disease had yet to stop rising in Africa, that infection rates continued to increase and that the epicentre had moved to Asian nations.

What is more, there is no cure for AIDS. Once treatment is initiated, experience points toward two certainties: first, drug resistance will inevitably set in among a certain percentage each year—even in the best of medical environments—and, second, medical-care costs increase over time. Many cancers, however, can be treated cheaply if caught in time: that kind of investment could have provided full cures for millions. For instance, Pact estimates that cervical cancer can be cured with 30 radiotherapy treatments at an average price of $5 per treatment.



Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org